These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24511294)

  • 21. Differential regulation of p53 function by the N-terminal ΔNp53 and Δ113p53 isoforms in zebrafish embryos.
    Davidson WR; Kari C; Ren Q; Daroczi B; Dicker AP; Rodeck U
    BMC Dev Biol; 2010 Oct; 10():102. PubMed ID: 20929554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer.
    Tsuda H; Hirohashi S
    Int J Cancer; 1994 May; 57(4):498-503. PubMed ID: 7910151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues.
    Iwaya K; Tsuda H; Fujita S; Suzuki M; Hirohashi S
    Lab Invest; 1995 Jun; 72(6):707-14. PubMed ID: 7540234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer.
    Balogh GA; Mailo DA; Corte MM; Roncoroni P; Nardi H; Vincent E; Martinez D; Cafasso ME; Frizza A; Ponce G; Vincent E; Barutta E; Lizarraga P; Lizarraga G; Monti C; Paolillo E; Vincent R; Quatroquio R; Grimi C; Maturi H; Aimale M; Spinsanti C; Montero H; Santiago J; Shulman L; Rivadulla M; Machiavelli M; Salum G; Cuevas MA; Picolini J; Gentili A; Gentili R; Mordoh J
    Int J Oncol; 2006 Apr; 28(4):995-1002. PubMed ID: 16525651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
    Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
    J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 alterations in all stages of breast cancer.
    Davidoff AM; Kerns BJ; Pence JC; Marks JR; Iglehart JD
    J Surg Oncol; 1991 Dec; 48(4):260-7. PubMed ID: 1745051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
    Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
    Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical study of apoptotic marker p53 as a prognostic factor in breast cancer.
    Loskutova KS; Kirillina MP; Lushnikova EL; Nepomnyashchikh LM
    Bull Exp Biol Med; 2014 Nov; 158(1):84-7. PubMed ID: 25403404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between p53 status, DNA ploidy, proliferation rate and nuclear morphology in breast cancer. An image cytometric study.
    Friedrich K; Dimmer V; Haroske G; Meyer W; Theissig F; Kunze KD
    Anal Cell Pathol; 1997; 15(2):85-97. PubMed ID: 9413594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.
    Javeri A; Ghaffarpour M; Taha MF; Houshmand M
    Med Oncol; 2013 Mar; 30(1):413. PubMed ID: 23292869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
    Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
    Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma.
    Pezeshki AM; Farjadian S; Talei A; Vasei M; Gharesi-Fard B; Doroudchi M; Ghaderi A
    Cancer Lett; 2001 Aug; 169(1):69-75. PubMed ID: 11410327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2.
    Dhar G; Banerjee S; Dhar K; Tawfik O; Mayo MS; Vanveldhuizen PJ; Banerjee SK
    Cancer Res; 2008 Jun; 68(12):4580-7. PubMed ID: 18559502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.